Ser73

Site Information
ARARVsYsPAHARLT SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14573926

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 ) , western blotting ( 2 )
Disease tissue studied:	luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 5 ) , cervical adenocarcinoma ( 5 ) , leukemia ( 4 ) , acute myelogenous leukemia ( 4 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 2 ) , breast ( 1 ) , HeLa S3 (cervical) ( 5 ) , K562 (erythroid) ( 3 ) , KG-1 (myeloid) ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Katsumura KR, et al. (2014) Molecular basis of crosstalk between oncogenic Ras and the master regulator of hematopoiesis GATA-2. EMBO Rep 15, 938-47 25056917 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
5	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info